Multidrug efflux pumps in Staphylococcus aureus: An update

Open Microbiology Journal

Volumn 7, Issue SPEC.ISSUE.1, 2013, Pages 59-71

  Costa, Sofia Santos ^a,b   Viveiros, Miguel ^a,c   Amaral, Leonard ^a,c   Couto, Isabel ^a,b  

^a INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^b UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^c COST ACTION BM0701 ^*  (Belgium)

Author keywords

Antibiotics; Biocides; Efflux pumps; Multidrug resistance; Staphylococcus aureus

Indexed keywords

ACRIFLAVINE; ALANINE; AMIDINOHYDRAZONE; ASPARTIC ACID; BENZALKONIUM CHLORIDE; CETRIMIDE; CHLORAMPHENICOL; CHLORHEXIDINE; CIPROFLOXACIN; COTRIMOXAZOLE; DEQUALINIUM; DODECYL SULFATE SODIUM; ERYTHROMYCIN; ETHIDIUM BROMIDE; FLORFENICOL; FUSIDIC ACID; GARENOXACIN; KANAMYCIN; LINEZOLID; MOXIFLOXACIN; NORFLOXACIN; NOVOBIOCIN; PENTAMIDINE; PSEUDOMONIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RHODAMINE; TETRAPHENYLPHOSPHONIUM; TIGECYCLINE; VIRGINIAMYCIN;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; BACILLUS SUBTILIS; BACTERIAL CHROMOSOME; BACTERIAL GENE; BACTERIAL GENOME; BACTERIAL PHENOMENA AND FUNCTIONS; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CLOSTRIDIUM DIFFICILE; ESCHERICHIA COLI; GENE DELETION; GENE FUNCTION; GENE INSERTION; GENE OVEREXPRESSION; GENE REGULATORY NETWORK; GENETIC VARIABILITY; LMRS GENE; MDEA GENE; MEPA GENE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANCE EFFLUX PUMP; MUTATIONAL ANALYSIS; NEISSERIA GONORRHOEAE; NONHUMAN; NORA GENE; NORB GENE; NORC GENE; PHENOTYPE; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; QACA GENE; QACB GENE; QACG GENE; QACH GENE; QACJ GENE; REVIEW; SDRM GENE; SEPA GENE; SEQUENCE HOMOLOGY; SKIN ABSCESS; SMR GENE; SPECIES DIFFERENCE; STAPHYLOCOCCUS AUREUS; VIBRIO PARAHAEMOLYTICUS;

STAPHYLOCOCCUS AUREUS;

EID: 84876097865     PISSN: None     EISSN: 18742858     Source Type: Journal    
DOI: 10.2174/1874285801307010059     Document Type: Review

References (152)

1. Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 2010; 74: 417-33.
2. Rice LB. The clinical consequences of antimicrobial resistance. Curr Opin Microbiol 2009; 12: 1-6.
3. Livermore DM. Has the era of untreatable infections arrived? J Antimicrob Chemother 2009; 64(S1): i29-36.
4. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339: 520-32.
5. Chambers HF, DeLeo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 2009; 7: 629-41.
6. David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev 2010; 23: 616-87.
7. Piddock LJV. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev 2006; 19: 382-402.
8. Alekshun MN, Levy SB. Molecular mechanisms of antibacterial multidrug resistance. Cell 2007; 128: 1037-50.
9. Piddock LJV. Multidrug-resistance efflux pumps not just for resistance. Nat Rev Microbiol 2006; 4: 629-36.
10. Poole K. Bacterial multidrug efflux pumps serve other functions. Microbe 2008; 3: 179-85.
11. Kumar A, Schweizer HP. Bacterial resistance to antibiotics: active efflux and reduced uptake. Adv Drug Deliv Rev 2005; 57: 1486-513.
12. Ubukata K, Itoh-Yamashita N, Konno M. Cloning and expression of the norA gene for fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1989; 33: 1535-9.
13. Schmitz FJ, Hertel B, Hofmann B, et al. Relationship between mutations in the coding and promoter regions and the norA genes in 42 unrelated clinical isolates of Staphylococcus aureus and the MICs of norfloxacin for these strains. J Antimicrob Chemother 1998; 42: 561-3.
14. Sierra JM, Ruiz J, de Anta MTJ, et al. Prevalence of two different genes encoding NorA in 23 clinical strains of Staphylococcus aureus. J Antimicrob Chemother 2000; 46: 145-6.
15. Noguchi N, Okada H, Narui K, et al. Comparison of the nucleotide sequence and expression of norA genes and microbial susceptibility in 21 strains of Staphylococcus aureus. Microb Drug Resist 2004; 10: 197-203.
16. Yoshida, H, Bogaki M, Nakamura S, et al. Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones. J Bacteriol 1990; 172: 6942-9.
17. Neyfakh AA. The multidrug efflux transporter of Bacillus subtilis is a structural and functional homolog of the Staphylococcus aureus NorA protein. Antimicrob Agents Chemother 1992; 36: 484-5.
18. Neyfakh AA, Borsch CM, Kaatz GW. Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux trans-porter. Antimicrob Agents Chemother 1993; 37: 128-9.
19. Kaatz GW, Seo SM, Ruble CA. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1993; 37: 1086-94.
20. Kaatz GW, Seo SM. Inducible NorA-mediated multidrug resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1995; 39: 2650-5.
21. Ng EYW, Trucksis M, Hooper DC. Quinolone resistance mediated by norA: physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromo-some. Antimicrob Agents Chemother 1994; 38: 1345-55.
22. Couto I, Costa SS, Viveiros M, et al. Efflux-mediated response of Staphylococcus aureus exposed to ethidium bromide. J Antimicrob Chemother 2008; 62: 504-13.
23. Kaatz GW, Seo SM. Mechanisms of fluoroquinolone resistance in genetically related strains of Staphylococcus aureus. Antimicrob Agents Chemother 1997; 41: 2733-7.
24. Kaatz GW, Seo SM. Effect of substrate exposure and other growth condition manipulations on norA expression. J Antimicrob Chemo-ther 2004; 54: 364-9.
25. Fournier B, Truong-Bolduc QC, Zhang X, et al. A mutation in the 5' untranslated region increases stability of norA mRNA, encoding a multidrug resistance transporter of Staphylococcus aureus. J Bacteriol 2001; 183: 2367-71.
26. Kaatz GW, Thyagarajan RV, Seo SM. Effect of promoter region mutations and mgrA overexpression on transcription of norA, which encodes a Staphylococcus aureus multidrug efflux trans-porter. Antimicrob Agents Chemother 2005; 49:161-9.
27. DeMarco CE, Cushing LA, Frempong-Manso E, et al. Efflux-related resistance to norfloxacin, dyes, and biocides in bloodstream isolates of Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51: 3235-9.
28. Huet AA, Raygada JL, Mendiratta K, et al. Multidrug efflux pump overexpression in Staphylococcus aureus after single and multiple in vitro exposures to biocides and dyes. Microbiol 2008; 154: 3144-53.
29. Kaatz GW, Seo SM, O'Brien L, et al. Evidence for the existence of a multidrug efflux pump transporter distinct from NorA in Staphylococcus aureus. Antimicrob Agents Chemother 2000; 44: 1404-6.
30. Kaatz GW, Moudgal VV, Seo SM. Identification and characterization of a novel efflux-related multidrug resistance phenotype in Staphylococcus aureus. J Antimicrob Chemother 2002; 50: 833-8.
31. Truong-Bolduc QC, Dunman PM, Strahilevitz J, et al. MgrA is a multiple regulator of two new efflux pumps in Staphylococcus aureus. J Bacteriol 2005; 187: 2395-405.
32. Ding Y, Onodera Y, Lee JC, et al. NorB, an efflux pump in Staphylococcus aureus strain MW2, contributes to bacterial fitness in abscesses. J Bacteriol 2008; 190: 7123-9.
33. Truong-Bolduc QC, Bolduc GR, Okumura R, et al. Implication of the NorB efflux pump in the adaptation of Staphylococcus aureus to growth at acid pH and in resistance to moxifloxacin. Antimicrob Agents Chemother 2011; 55: 3214-9.
34. Truong-Bolduc QC, Hsing LC, Villet R, et al. Reduced aeration affects the expression of the NorB efflux pump of Staphylococcus aureus by posttranslational modification of MgrA. J Bacteriol 2012; 194: 1823-34.
35. Truong-Bolduc QC, Strahilevitz J, Hooper DC. NorC, a new efflux pump regulated by MgrA of Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 1104-7.
36. Truong-Bolduc QC, Dunman PM, Eidem T, et al. Transcriptional profiling analysis of the global regulator NorG, a GntR-like protein of Staphylococcus aureus. J Bacteriol 2011; 193: 6207-14.
37. Kaatz GW, McAleese F, Seo SM. Multidrug resistance in Staphylococcus aureus due to overexpression of a novel multidrug and toxin extrusion (MATE) transport protein. Antimicrob Agents Chemother 2005; 49: 1857-64.
38. McAleese F, Petersen P, Ruzin A, et al. A novel MATE family efflux pump contributes to the reduced susceptibility of laboratoryderived Staphylococus aureus mutants to tigecycline. Antimicrob Agents Chemother 2005; 49: 1865-71.
39. Huang J, O'Toole PW, Shen W, et al. Novel chromosomally encoded multidrug efflux transporter MdeA in Staphylococcus aureus. Antimicrob Agents Chemother 2004: 48: 909-17.
40. Yamada Y, Shiota S, Mizushima T, et al. Functional gene cloning and characterization of MdeA, a multidrug efflux pump from Staphylococcus aureus. Biol Pharm Bull 2006; 29: 801-4.
41. Narui K, Noguchi N, Wakasugi K, et al. Cloning and characterization of a novel chromosomal drug efflux gene in Staphylococcus aureus. Biol Pharm Bull 2002; 25: 1533-6.
42. Yamada Y, Hideka K-I, Shiota S, et al. Gene cloning and characterization of SdrM, a chromosomally-encoded multidrug efflux pump, from Staphylococcus aureus. Biol Pharm Bull 2006; 29: 554-6.
43. Floyd JL, Smith KP, Kumar SH, et al. LmrS is a multidrug efflux pump of the Major Facilitator Superfamily from Staphylococcus aureus. Antimicrob Agents Chemother 2010; 54: 5406-12.
44. Tennent JM, Lyon BR, Gillespie MT, et al. Cloning and expression of Staphylococcus aureus plasmid-mediated quaternary ammonium resistance in Escherichia coli. Antimicrob Agents Chemother 1985; 27: 79-83.
45. Rouch DA, Cram DS, DiBerardino D, et al. Efflux-mediated antiseptic resistance gene qacA from Staphylococcus aureus: common ancestry with tetracycline-and sugar-transport proteins. Mol Microbiol 1990; 4: 2051-62.
46. Leelaporn A, Paulsen IT, Tennent JM, et al. Multidrug resistance to antiseptics and disinfectants in coagulase-negative staphylococci. J Med Microbiol 1994; 40: 214-20.
47. Tennent JM, Lyon BR, Midgley M, et al. Physical and biochemical characterization of the qacA gene encoding antiseptic and disinfectant resistance in Staphylococcus aureus. J Gen Microbiol 1989; 135:1-10.
48. Mitchell BA, Brown MH, Skurray RA. QacA multidrug efflux pump from Staphylococcus aureus: comparative analysis of resistance to diamidines, biguanidines, and guanylhydrazones. Antimicrob Agents Chemother 1998; 42: 475-7.
49. Brown MH, Skurray RA. Staphylococcal multidrug efflux pump protein QacA. J Mol Microbiol Biotechnol 2001; 3: 163-70.
50. Mitchell BA, Paulsen IT, Brown MH, et al. Bioenergetics of the Staphylococcal multidrug export protein QacA. J Biol Chem 1999; 274: 3541-8.
51. Paulsen IT, Brown MH, Skurray RA. Characterization of the earliest known Staphylococcus aureus plasmid encoding a multidrug efflux system. J Bacteriol 1998; 180: 3477-9.
52. Lyon BR, Skurray R. Antimicrobial resistance of Staphylococcus aureus: genetic basis. Microbiol Rev 1987; 51: 88-134.
53. Paulsen IT, Brown MH, Littlejohn TG, et al. Multidrug resistance proteins QacA and QacB from Staphylococcus aureus: membrane topology and identification of residues involved in substrate specificity. Proc Natl Acad Sci USA 1996; 93: 3630-5.
54. Xu Z, O'Rourke BA, Skurray RA, et al. Role of transmembrane segment 10 in efflux mediated by the staphylococcal multidrug transport protein QacA. J Biol Chem 2006; 281: 792-9.
55. Alam MM, Kobayashi N, Uehara N, et al. Analysis on distribution and genomic diversity of high-level antiseptic resistance genes qacA and qacB in human clinical isolates of Staphylococcus aureus. Microb Drug Resist 2003; 9: 109-21.
56. Nakaminami H, Noguchi N, Sasatsu M. Fluoroquinolone efflux by the plasmid-mediated multidrug efflux pump QacB variant QacBIII in Staphylococcus aureus. Antimicrob Agents Chemother 2010; 54: 4107-11.
57. Sasatsu M, Shima K, Shibata Y, et al. Nucleotide sequence of a gene that encodes resistance to ethidium bromide from a transferable plasmid in Staphylococcus aureus. Nucleic Acids Res 1989; 17: 10103.
58. Littlejohn TG, DiBerardino D, Messerotti LJ, et al. Structure and evolution of a family of genes encoding antiseptic and disinfectant resistance in Staphylococcus aureus. Gene 1991; 101: 59-66.
59. Grinius L, Dreguniene G, Goldberg EB, et al. A staphylococcal multidrug resistance gene product is a member of a new protein family. Plasmid 1992; 27: 119-29.
60. Leelaporn A, Firth N, Paulsen IT, et al. Multidrug resistance plasmid pSK108 from coagulase-negative staphylococci; relationships to Staphylococcus aureus qacC plasmids. Plasmid 1995; 34: 62-7.
61. Grinius LL, Goldberg EB. Bacterial multidrug resistance is due to a single membrane protein which functions as a drug pump. J Biol Chem 1994; 269: 29998-30004.
62. Paulsen IT, Brown MH, Dunstan SJ, et al. Molecular characterization of the staphylococcal multidrug resistance export protein QacC. J Bacteriol 1995; 177: 2827-33.
63. Bay DC, Rommens KL, Turner RJ. Small multidrug resistance proteins: a multidrug transporter family that continues to grow. Biochim Biophys Acta 2008; 1778: 1814-38.
64. Heir E, Sundheim G, Holck AL. Resistance to quaternary ammonium compounds in Staphylococcus spp. isolated from the food industry and nucleotide sequence of the resistance plasmid pST827. J Appl Bacteriol 1995; 79: 149-56.
65. Bjorland J, Sunde M, Waage S. Plasmid-borne smr gene causes resistance to quaternary ammonium compounds in bovine Staphylococcus aureus. J Clin Microbiol 2001; 39: 3999-4004.
66. Alam MM, Ishino M, Kobayashi N. Analysis of genomic diversity and evolution of the low-level antiseptic resistance gene smr in Staphylococcus aureus. Microb Drug Resist 2003; 9(S1): S1-7.
67. Heir E, Sundheim G, Holck AL. The qacG gene on plasmid pST94 confers resistance to quaternary ammonium compounds in staphylococci isolates from the food industry. J Appl Microbiol 1999; 86: 378-88.
68. Heir E, Sundheim G, Holck AL. The Staphylococcus qacH gene product: a new member of the SMR family encoding multidrug resistance. FEMS Microbiol Lett 1998; 163: 49-56.
69. Bjorland J, Steinum T, Sunde M, et al. Novel plasmid-borne gene qacJ mediates resistance to quaternary ammonium compounds in equine Staphylococcus aureus, Staphylococcus simulans, and Staphylococcus intermedius. Antimicrob Agents Chemother 2003; 47: 3046-52.
70. Fournier B, Aras R, Hooper DC. Expression of the multidrug resistance transporter NorA from Staphylococcus aureus is modified by a two-component regulatory system. J Bacteriol 2000; 182: 664-71.
71. Luong TT, Newell SW, Lee CY. mgr, a novel global regulator in Staphylococcus aureus. J Bacteriol 2003; 185: 3703-10.
72. Ingavale S, van Wamel W, Cheung AL. Characterization of RAT, an autolysis regulator in Staphylococcus aureus. Mol Microbiol 2003; 48: 1451-66.
73. Chen PR, Bae T, Williams WA, et al. An oxidation-sensing mechanism is used by the global regulator MgrA in Staphylococcus aureus. Nat Chem Biol 2006; 2: 591-5.
74. Ingavale S, van Wamel W, Luong TT, et al. Rat/MgrA, a regulator of virulence genes in Staphylococcus aureus. Infect Immun 2005; 73: 1423-31.
75. Luong TT, Dunman PM, Murphy E, et al. Transcription profiling of the mgrA regulon in Staphylococcus aureus. J Bacteriol 2006; 188: 1899-910.
76. Cheung AL, Nishina KA, Trotonda MP, et al. The SarA protein family of Staphylococcus aureus. Int J Biochem Cell Biol 2008; 40: 355-61.
77. B regulon in Staphylococcus aureus. J Bacteriol 2000; 182: 6983-91.
78. B regulon. J Bacteriol 2004; 186: 4085-99.
79. Truong-Bolduc QC, Zhang X, Hooper DC. Characterization of NorR protein, a multifunctional regulator of norA expression in Staphylococcus aureus. J Bacteriol 2003; 185: 3127-38.
80. Truong-Bolduc QC, Hooper DC. The transcriptional regulators NorG and MgrA modulate resistance to both quinolones and β-lactams in Staphylococcus aureus. J Bacteriol 2007; 189: 2996-3005.
81. Truong-Bolduc QC, Ding Y, Hooper DC. Posttranslational modification influences the effects of MgrA on norA expression in Staphylococcus aureus. J Bacteriol 2008; 190: 7375-81.
82. Truong-Bolduc QC, Hooper DC. Phosphorylation of MgrA and its effect on expression of the NorA and NorB efflux pumps of Staphylococcus aureus. J Bacteriol 2010; 192: 2525-34.
83. Chen PR, Nishida S, Poor CB, et al. A new oxidative sensing and regulation pathway mediated by the MgrA homologue SarZ in Staphylococcus aureus. Mol Microbiol 2008; 71: 198-211.
84. Kosmidis C, DeMarco C, Frempong-Manso E, et al. In silico correlations of multidrug efflux pump gene expression in Staphylococcus aureus. Int J Antimicrob Agents 2010; 36: 222-9.
85. Fournier B, Hooper DC. A new two-component regulatory system involved in adhesion, autolysis and extracellular proteolytic activity of Staphylococcus aureus. J Bacteriol 2000; 182: 3955-64.
86. Liang X, Zheng L, Landwehr C, et al. Global regulation of gene expression by ArlRS, a two-component signal transduction regulatory system of Staphylococcus aureus. J Bacteriol 2005; 187: 5486-92.
87. Deng X, Ji Q, Liang H, et al. Expression of multidrug resistance efflux pump gene norA is iron responsive in Staphylococcus aureus. J Bacteriol 2012; 194: 1753-62.
88. Kaatz GW, DeMarco CE, Seo SM. MepR, a repressor of the Staphylococcus aureus MATE family multidrug efflux pump MepA, is a substrate-responsive regulatory protein. Antimicrob Agents Chemother 2006; 50: 1276-81.
89. Kumaraswami M, Schuman JT, Seo SM, et al. Structural and biochemical characterization of MepR, a multidrug binding transcription regulator of the Staphyloocccus aureus multidrug efflux pump MepA. Nucleic Acids Res 2009; 37: 1211-24.
90. Opperman TJ, Williams JD, Houseweart C, et al. Efflux-mediated bis-indole resistance in Staphylococcus aureus reveals differential substrate specificities for MepA and MepR. Bioorg Med Chem 2010; 18: 2123-30.
91. Grkovic S, Brown MH, Roberts NJ, et al. QacR is a repressor protein that regulates expression of the Staphylococcus aureus multidrug efflux pump QacA. J Biol Chem 1998; 273: 18665-73.
92. Grkovic S, Brown MH, Schumacher MA, et al. The staphylococcal QacR multidrug regulator binds a correctly spaced operator as a pair of dimers. J Bacteriol 2001; 183: 7102-9.
93. Schumacher MA, Miller MC, Grkovic S, et al. Structural basis for cooperative DNA binding by two dimers of the multidrug-binding protein QacR. EMBO J 2002; 21: 1210-8.
94. Schumacher MA, Miller MC, Grkovic S, et al. Structural mechanisms of QacR induction and multidrug recognition. Science 2001; 294: 2158-63.
95. Grkovic S, Hardie KM, Brown MH, et al. Interactions of the QacR multidrug-binding protein with structurally diverse ligands: implications for the evolution of the binding pocket. Biochemistry 2003; 42: 15226-36.
96. Schmitz F-J, Fluit AC, Lückefahr M, et al. The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 1998; 42: 807-10.
97. Muñoz-Bellido JL, Manzanares MAA, Martínez JÁ, et al. Efflux pump-mediated quinolones resistance in Staphylococcus aureus strains wild-type for gyrA, gyrB, grlA, and norA. Antimicrob Agents Chemother 1999; 43: 354-6.
98. Noguchi N, Okihara T, Namiki Y, et al. Susceptibility and resistance genes to fluoroquinolones in methicillin-resistant Staphylococcus aureus isolated in 2002. Int J Antimicrob Agents 2005; 25: 374-9.
99. Lomovskaya O, Waltkins W. Inhibition of efflux pumps as a novel approach to combat drug resistance in bacteria. J Mol Microbiol Biotechnol. 2001; 3: 225-36.
100. Amaral L, Viveiros M, Kristiansen JE. Non-Antibiotics: alternative therapy for the management of MDRTB and MRSA in economically disadvantaged countries. Curr Drug Targets 2006; 7: 887-91.
101. Marquez B. Bacterial efflux systems and efflux pump inhibitors. Biochimie 2005; 87: 1137-47.
102. Frempong-Manso E, Raygada JL, DeMarco CE, et al. Inability of a reserpine-based screen to identify strains overexpressing efflux pump genes in clinical isolates of Staphylococcus aureus. Int J Antimicrob Agents 2009; 33: 360-3.
103. Pagès JM, Amaral L. Mechanisms of drug efflux and strategies to combat them: challenging the efflux pump of Gram-negative bacteria. Biochim Biophys Acta 2009; 1794: 826-33.
104. Patel D, Kosmidis C, Seo SM, et al. Ethidium bromide MIC screening for enhanced efflux pump gene expression or efflux activity in Staphylococcus aureus. Antimicrob Agents Chemother 2010; 54: 5070-3.
105. Costa SS, Falcão C, Viveiros M, et al. Exploring the contribution of efflux on the resistance to fluoroquinolones in clinical isolates of Staphylococcus aureus. BMC Microbiol 2011; 11: e241.
106. Martins M, Viveiros M, Couto I, et al. Identification of efflux pump-mediated multidrug-resistant bacteria by the Ethidium Bromide-Agar Cartwheel Method. In Vivo 2011; 25: 171-8.
107. Viveiros M, Rodrigues L, Martins M, et al. Antibiotic Resistance Protocols. In: Gillespie SH, McHugh TD, Eds. Evaluation of efflux activity of bacteria by a semi-automated fluorometric system. New York: Humana Press 2010; pp. 159-72.
108. Poole K. Efflux pumps as antimicrobial resistance mechanisms. Ann Med 2007 39: pp. 162-76.
109. Ferrero L, Cameron B, Crouzet J. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother 1995; 39: 1554-8.
110. Ng EY, Trucksis M, Hooper DC. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob Agents Chemother 1996; 40: 1881-8.
111. Hooper DC. Mechanisms of fluoroquinolone resistance. Drug Resist Updat 1999; 2: 38-55.
112. Tanaka M, Zhang YX, Ishida H, et al. Mechanisms of 4-quinolone resistance in quinolones-resistant and methicillin-resistant Staphylococcus aureus isolates from Japan and China. J Med Microbiol 1995; 42: 214-9.
113. Schmitz F-J, Köhrer K, Scheuring S, et al. The stability of grlA, grlB, gyrA, gyrB and norA mutations and MIC values of five fluoroquinolones in three different clonal populations of methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 1999; 5: 287-90.
114. Schmitz F-J, Fluit AC, Brisse S, et al. Molecular epidemiology of quinolones resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates. FEMS Immunol Med Microbiol 1999; 26: 281-7.
115. Guirao GY, Toldos MCM, Peris BM, et al. Molecular diversity of quinolones resistance in genetically related clinical isolates of Staphylococcus aureus and susceptibility to newer quinolones. J Antimicrob Chemother 2001; 47: 157-61.
116. Horii T, Suzuki Y, Morita M, et al. Detection of mutations in quinolone resistance-determining regions in levofloxacin-and methicillin-resistant Staphylococcus aureus: effects of the mutations on fluoroquinolone MICs. Diagn Microbiol Infect Dis 2003; 46: 139-45.
117. Hernández A, Sánchez MB, Martínez JL. Quinolone resistance: much more than predicted. Front Microbiol 2011; 2: e22.
118. SCENIHR (Scientific Committee on Emerging and Newly Identified Health Risks), Assessment of the Antibiotic Resistance Effects of Biocides [Accessed on: 19 January 2009] Available on http://ec.eropa.eu/health/ph_risk/committees/04_scenihr/docs/scenihr_o_021.pdf
119. Chaplin CE. Bacterial resistance to quaternary ammonium disinfectants. J Bacteriol 1951; 63: 453-8.
120. Russell AD. Introduction of biocides into clinical practice and the impact on antibiotic-resistant bacteria. J Appl Microbiol 2002; 92: 121S-35.
121. Weber DJ, Rutala WA, Sickbert-Bennett EE. Outbreaks associated with contaminated antiseptics and disinfectants. Antimicrob Agents Chemother 2007; 51: 4217-24.
122. Buffet-Bataillon S, Tattevin P, Bonnaure-Mallet M, et al. Emergence of resistance to antibacterial agents: the role of quaternary ammonium compounds-a critical review. Int J Antimicrob Agents 2012; 39: 381-9.
123. Noguchi N, Suwa J, Narui K, et al. Susceptibilities to antiseptics and distribution of antiseptic-resistance genes qacA/B and smr of methicillin-resistance Staphylococcus aureus isolated in Asia during 1998 and 1999. J Med Microbiol 2005; 54: 557-65.
124. Sheng W-H, Wang J-T, Lauderdale T-L, et al. Epidemiology and susceptibilities of methicillin-resistant Staphylococcus aureus in Taiwan: emphasis on chlorhexidine susceptibility. Diagn Microbiol Infect Dis 2009; 63: 309-13.
125. Sekiguchi J-I, Hama T, Fujino T, et al. Detection of the antiseptic-and disinfectant-resistance genes qacA, qacB, and qacC in methicillin-resistant Staphylococcus aureus isolated in a Tokyo hospital. Jpn J Infect Dis 2004; 57: 288-91.
126. Noguchi N, Nakaminami H, Nishijima S, et al. Antimicrobial agent of susceptibilities and antiseptic resistance gene distribution among methicillin-resistant Staphylococcus aureus isolates from patients with impetigo and staphylococcal scalded skin syndrome. J Clin Microbiol 2006; 44: 2119-25.
127. Mayer S, Boos M, Beyer A, et al. Distribution of the antiseptic resistance genes qacA, qacB, and qacC in 497 methicillin-resistant and -susceptible European isolates of Staphylococcus aureus. J Antimicrob Chemother 2001; 47: 893-5.
128. Vali L, Davies SE, Lai LLG, et al. Frequency of biocide resistance genes, antibiotic resistance and the effect of chlorhexidine exposure on clinical methicillin-resistant Staphylococcus aureus isolates. J Antimicrob Chemother 2008; 61: 524-32.
129. Smith K, Gemmell CG, Hunter IS. The association between biocide tolerance and the presence or absence of qac genes among hospitalacquired and community-acquired MRSA isolates. J Antimicrob Chemother 2008; 61: 78-84.
130. Zmantar T, Kouidhi B, Miladi H, et al. Detection of macrolide and disinfectant resistance genes in clinical Staphylococcus aureus and coagulase-negative staphylococci. BMC Res Notes 2011; 4: e453.
131. Longtin J, Seah C, Siebert K, et al. Distribution of antiseptic resistance genes qacA, qacB, and smr in methicillin-resistant Staphylococcus aureus isolated in Toronto, Canada, from 2005 to 2009. Antimicrob Agents Chemother 2011; 55: 2999-3001.
132. Bjorland J, Steinum T, Kvitle B, et al. Widespread distribution of disinfectant resistance genes among staphylococci of bovine and caprine origin in Norway. J Clin Microbiol 2005; 43: 4363-8.
133. Ye M-F, Zhang M, O'Donoghue M, et al. Are qacG, qacH and qacJ genes transferring from food isolates to carriage isolates of staphylococci? J Hosp Infect 2012; 80: 95-6.
134. Costa SS, Ntokou E, Martins A, et al. Identification of the plasmid-encoded qacA efflux pump gene in meticillin-resistant Staphylococcus aureus (MRSA) strain HPV107, a representative of the MRSA Iberian clone. Int J Antimicrob Agents 2010; 36: 557-61.
135. Maillard J-Y. Bacterial resistance to biocides in the healthcare environment: should it be of genuine concern? J Hosp Infect 2007; 65: 60-72.
136. Meyer B, Cookson B. Does microbial resistance or adaptation to biocides create a hazard in infection prevention and control? J Hosp Infect 2010; 76: 200-5.
137. Suller MTE, Russell AD. Antibiotic and biocide resistance in methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus. J Hosp Infect 1999; 43: 281-91.
138. Walsh SE, Maillard J-Y, Russell AD, et al. Development of bacterial resistance to several biocides and effects on antibiotic susceptibility. J Hosp Infect 2003; 55: 98-107.
139. Narui K, Takano M, Noguchi N, et al. Susceptibilities of methicillin-resistant Staphylococcus aureus isolates to seven biocides. Biol Pharm Bull 2007; 30: 585-7.
140. Thorrold CA, Letsoalo ME, Dusé AG, et al. Efflux pump activity in fluoroquinolone and tetracycline resistant Salmonella and E. coli implicated in reduced susceptibility to household antimicrobial cleaning agents. Int J Food Microbiol 2007; 113: 315-20.
141. Wootton M, Walsh TR, Davies EM, et al. Evaluation of the effectiveness of common hospital hand disinfectants against methicillinresistant Staphylococcus aureus, glycopeptides-intermediate S. aureus, and heterogeneous glycopeptides-intermediate S. aureus. Infect Control Hosp Epidemiol 2009; 30: 226-32.
142. Anthonisen I-L, Sunde M, Steinum TM, et al. Organization of the antiseptic resistance gene qacA and Tn552-related β-lactamase genes in multidrug-resistant Staphylococcus haemolyticus strains of animal and human origins. Antimicrob Agents Chemother 2002; 46: 3606-12.
143. Sidhu MS, Heir E, Leegaard T, et al. Frequency of disinfectant resistance genes and genetic linkage with β-lactamase transposon Tn552 among clinical staphylococci. Antimicrob Agents Chemother. 2002; 46: 2797-803.
144. Jensen SO, Apisiridej S, Kwong SM, et al. Analysis of the prototypical Staphylococcus aureus multiresistance plasmid pSK1. Plasmid 2010; 64: 135-42.
145. Berg T, Firth N, Apisiridej S, et al. Complete nucleotide sequence of pSK41: evolution of staphylococcal conjugative multiresistance plasmids. J Bacteriol 1998; 180: 4350-9.
146. Nakaminami H, Noguchi N, Nishijima S, et al. Characterization of the pTZ2162 encoding multidrug efflux gene qacB from Staphylococcus aureus. Plasmid 2008; 60: 108-17.
147. Lambert RJW. Comparative analysis of antibiotic and antimicrobial biocide susceptibility data in clinical isolates of methicillinsensitive Staphylococcus aureus, methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa between 1989 and 2000. J Appl Microbiol 2004; 97: 699-711.
148. Zhang M, O'Donoghue MM, Ito T, et al. Prevalence of antisepticresistance genes in Staphylococcus aureus and coagulase-negative staphylococci colonizing nurses and the general population in Hong Kong. J Hosp Infect 2011; 78: 113-8.
149. Singh R, Swick MC, Ledesma KR, et al. Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli. Antimicrob Agents Chemother 2012; 56: 1680-5.
150. Machado D, Couto I, Perdigão J, et al. Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis. PLoS ONE 2012; 7: e34538.
151. Markham PN, Neyfakh AA. Inhibition of the multidrug transporter NorA prevents emergence of norfloxacin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1996; 40: 2673-4.
152. Sulavik MC, Barg NL. Examination of methicillin-resistant and methicillin-susceptible Staphylococcus aureus mutants with lowlevel fluoroquinolone resistance. Antimicrob Agents Chemother 1998; 42: 3317-9.